Proposed INN: List 104 <strong>WHO</strong> <strong>Drug</strong> <strong>Information</strong>, <strong>Vol</strong>. <strong>24</strong>, <strong>No</strong>. 4, <strong>2010</strong>burixaforumburixaforburixaforburixafor(2-{4-[6-amino-2-({[(1r,4r)-4-({[3-(cyclohexylamino)propyl]amino}methyl)cyclohexyl]methyl}amino)pyrimidin-4-yl]piperazin-1-yl}ethyl)phosphonic acidchemokine CXCR 4 receptor antagonistacide (2-{4-[6-amino-2-({[(1r,4r)-4-({[3-(cyclohexylamino)propyl]amino}méthyl)cyclohexyl]méthyl}amino)pyrimidin-4-yl]pipérazin-1-yl}éthyl)phosphoniqueantagoniste du récepteur de chimiokine CXCR4ácido (2-{4-[6-amino-2-({[(1r,4r)-4-({[3-(ciclohexilamino)propil]amino}metil)ciclohexil]metil}amino)pirimidin-4-il]piperazin-1-il}etil)fosfónicoantagonista del receptor (CXCR4) de quimiokinaC 27 H 51 N 8 O 3 P 1191448-17-5ONHNHHNNNNP OHOHNNH 2cadazolidumcadazolidcadazolidcadazolid1-cyclopropyl-6-fluoro-7-[4-({2-fluoro-4-[(5R)-5-(hydroxymethyl)-2-oxo-1,3-oxazolidin-3-yl]phenoxy}methyl)-4-hydroxypiperidin-1-yl]-4-oxo-1,4-dihydroquinolin-3-carboxylic acidantibacterialacide 1-cyclopropyl-6-fluoro-7-[4-({2-fluoro-4-[(5R)-5-(hydroxyméthyl)-2-oxo-1,3-oxazolidin-3-yl]phénoxy}méthyl)-4-hydroxypipéridin-1-yl]-4-oxo-1,4-dihydroquinoléine-3-carboxyliqueantibactérienácido 1-ciclopropil-6-fluoro-7-[4-({2-fluoro-4-[(5R)-5-(hidroximetil)-2-oxo-1,3-oxazolidin-3-il]fenoxi}metil)-4-hidroxipiperidin-1-il]-4-oxo-1,4-dihidroquinolin-3-carboxílicoantibacterianoC 29 H 29 F 2 N 3 O 8 1025097-10-2HOHONOOHOFNNFOCO 2 H360
<strong>WHO</strong> <strong>Drug</strong> <strong>Information</strong>, <strong>Vol</strong>. <strong>24</strong>, <strong>No</strong>. 4, <strong>2010</strong> Proposed INN: List 104carlumabum #carlumabcarlumabcarlumabimmunoglobulin G1-kappa, anti-[Homo sapiens CCL2 (chemokine(C-C motif) ligand 2, C-C motif chemokine 2, monocytechemoattractant protein-1, MCP-1, monocyte chemotactic andactivating factor, MCAF, small inducible cytokine A2, SCYA2,HC11)], Homo sapiens monoclonal antibody;gamma1 heavy chain (1-449) [Homo sapiens VH (IGHV1-69*01(99.00%) -(IGHD)-IGHJ4*01 [8.8.12] (1-119) -IGHG1*01 (120-449)],(222-216')-disulfide with kappa light chain (1'-216') [Homo sapiens V-KAPPA (IGKV3-11*01 (94.50%) -IGKJ1*01) [7.3.10] (1'-109') -IGKC*01 (110'-216')]; (228-228'':231-231'')-bisdisulfide dimerimmunomodulatorimmunoglobuline G1-kappa, anti-[Homo sapiens CCL2 (chimiokine(C-C motif) ligand 2, C-C motif chimiokine 2, protéine 1chimioattractante du monocyte, MCP-1, facteur activateur etchimiotactique du monocyte, MCAF, SCYA2, HC11)], Homo sapiensanticorps monoclonal;chaîne lourde gamma1 (1-449) [Homo sapiens VH (IGHV1-69*01(99.00%) -(IGHD)-IGHJ4*01 [8.8.12] (1-119) -IGHG1*01 (120-449)],(222-216')-disulfure avec la chaîne légère kappa (1'-216') [Homosapiens V-KAPPA (IGKV3-11*01 (94.50%) -IGKJ1*01) [7.3.10] (1'-109') -IGKC*01 (110'-216')]; dimère (228-228'':231-231'')-bisdisulfureimmunomodulateurinmunoglobulina G1-kappa, anti-[Homo sapiens CCL2 (quimiokina(C-C motif) ligando 2, C-C motif quimiokina 2, proteìna 1quimiotàctica de monocito, MCP-1, factor activador y quimiotàcticode monocito, MCAF, SCYA2, HC11)], anticuerpo monoclonal deHomo sapiens;cadena pesada gamma1 (1-449) [Homo sapiens VH (IGHV1-69*01(99.00%) -(IGHD)-IGHJ4*01 [8.8.12] (1-119) -IGHG1*01 (120-449)],(222-216')-disulfuro con la cadena ligera kappa (1'-216') [Homosapiens V-KAPPA (IGKV3-11*01 (94.50%) -IGKJ1*01) [7.3.10] (1'-109') -IGKC*01 (110'-216')]; dìmero (228-228'':231-231'')-bisdisulfuroinmunomodulador915404-94-3Heavy chain / Chaîne lourde / Cadena pesadaQVQLVQSGAE VKKPGSSVKV SCKASGGTFS SYGISWVRQA PGQGLEWMGG 50IIPIFGTANY AQKFQGRVTI TADESTSTAY MELSSLRSED TAVYYCARYD 100GIYGELDFWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSSVVTV PSSSLGTQTY 200ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPELLGGP SVFLFPPKPK 250DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL 400DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK 449Light chain / Chaîne légère / Cadena ligeraEIVLTQSPAT LSLSPGERAT LSCRASQSVS DAYLAWYQQK PGQAPRLLIY 50DASSRATGVP ARFSGSGSGT DFTLTISSLE PEDFAVYYCH QYIQLHSFTF 100GQGTKVEIKR TVAAPSVFIF PPSDEQLKSG TASVVCLLNN FYPREAKVQW 150KVDNALQSGN SQESVTEQDS KDSTYSLSST LTLSKADYEK HKVYACEVTH 200QGLSSPVTKS FNRGEC 216Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuroIntra-H 22-96 146-202 263-323 369-42722''-96'' 146''-202'' 263''-323'' 369''-427''Intra-L 23'-89' 136'-196'23'''-89''' 136'''-196'''Inter-H-L 222-216' 222''-216'''Inter-H-H 228-228'' 231-231''N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación299, 299''361
- Page 1 and 2:
WHO Drug Information Vol. 24, No. 4
- Page 3 and 4:
WHO Drug Information Vol. 24, No. 4
- Page 5 and 6:
WHO Drug Information Vol. 24, No. 4
- Page 7 and 8:
WHO Drug Information Vol. 24, No. 4
- Page 9 and 10:
WHO Drug Information Vol. 24, No. 4
- Page 11 and 12:
WHO Drug Information Vol. 24, No. 4
- Page 13 and 14:
WHO Drug Information Vol. 24, No. 4
- Page 15 and 16:
WHO Drug Information Vol. 24, No. 4
- Page 17 and 18:
WHO Drug Information Vol. 24, No. 4
- Page 19 and 20: WHO Drug Information Vol. 24, No. 4
- Page 21 and 22: WHO Drug Information Vol. 24, No. 4
- Page 23 and 24: WHO Drug Information Vol. 24, No. 4
- Page 25 and 26: WHO Drug Information Vol. 24, No. 4
- Page 27 and 28: WHO Drug Information Vol. 24, No. 4
- Page 29 and 30: WHO Drug Information Vol. 24, No. 4
- Page 31 and 32: WHO Drug Information Vol. 24, No. 4
- Page 33 and 34: WHO Drug Information Vol. 24, No. 4
- Page 35 and 36: WHO Drug Information Vol. 24, No. 4
- Page 37 and 38: WHO Drug Information Vol. 24, No. 4
- Page 39 and 40: WHO Drug Information Vol. 24, No. 4
- Page 41 and 42: WHO Drug Information Vol. 24, No. 4
- Page 43 and 44: WHO Drug Information Vol. 24, No. 4
- Page 45 and 46: WHO Drug Information Vol. 24, No. 4
- Page 47 and 48: WHO Drug Information Vol. 24, No. 4
- Page 49 and 50: WHO Drug Information Vol. 24, No. 4
- Page 51 and 52: WHO Drug Information Vol. 24, No. 4
- Page 53 and 54: WHO Drug Information Vol. 24, No. 4
- Page 55 and 56: WHO Drug Information Vol. 24, No. 4
- Page 57 and 58: WHO Drug Information Vol. 24, No. 4
- Page 59 and 60: WHO Drug Information Vol. 24, No. 4
- Page 61 and 62: WHO Drug Information, Vol. 24, No.
- Page 63 and 64: WHO Drug Information, Vol. 24, No.
- Page 65 and 66: WHO Drug Information, Vol. 24, No.
- Page 67 and 68: WHO Drug Information, Vol. 24, No.
- Page 69: WHO Drug Information, Vol. 24, No.
- Page 73 and 74: WHO Drug Information, Vol. 24, No.
- Page 75 and 76: WHO Drug Information, Vol. 24, No.
- Page 77 and 78: WHO Drug Information, Vol. 24, No.
- Page 79 and 80: WHO Drug Information, Vol. 24, No.
- Page 81 and 82: WHO Drug Information, Vol. 24, No.
- Page 83 and 84: WHO Drug Information, Vol. 24, No.
- Page 85 and 86: WHO Drug Information, Vol. 24, No.
- Page 87 and 88: WHO Drug Information, Vol. 24, No.
- Page 89 and 90: WHO Drug Information, Vol. 24, No.
- Page 91 and 92: WHO Drug Information, Vol. 24, No.
- Page 93 and 94: WHO Drug Information, Vol. 24, No.
- Page 95 and 96: WHO Drug Information, Vol. 24, No.
- Page 97 and 98: WHO Drug Information, Vol. 24, No.
- Page 99 and 100: WHO Drug Information, Vol. 24, No.
- Page 101 and 102: WHO Drug Information, Vol. 24, No.
- Page 103 and 104: WHO Drug Information, Vol. 24, No.
- Page 105 and 106: WHO Drug Information, Vol. 24, No.
- Page 107 and 108: WHO Drug Information, Vol. 24, No.
- Page 109 and 110: WHO Drug Information, Vol. 24, No.
- Page 111 and 112: WHO Drug Information, Vol. 24, No.
- Page 113 and 114: WHO Drug Information, Vol. 24, No.
- Page 115 and 116: WHO Drug Information, Vol. 24, No.
- Page 117 and 118: WHO Drug Information, Vol. 24, No.
- Page 119 and 120: WHO Drug Information, Vol. 24, No.
- Page 121 and 122:
WHO Drug Information, Vol. 24, No.
- Page 123 and 124:
WHO Drug Information, Vol. 24, No.
- Page 125 and 126:
WHO Drug Information, Vol. 24, No.
- Page 127 and 128:
WHO Drug Information, Vol. 24, No.